Nucleotide bisaminophosphate compound, pharmaceutical composition thereof, preparation method for nucleotide bisaminophosphate compound and application of nucleotide bisaminophosphate compound
The invention belongs to the technical field of medicines and discloses a nucleotide bisaminophosphate compound, a pharmaceutical composition thereof, a preparation method for the nucleotide bisaminophosphate compound and application of the nucleotide bisaminophosphate compound, particularly in treatment on novel-coronavirus pneumonia. Tests prove that the compound disclosed by the invention has the activity of inhibiting replication of 2019-nCoV virus; and meanwhile, the nucleotide bisaminophosphate compound has the advantages of higher in-vitro activity, bigger development coefficient and the like compared with a drug, i.e., Remdesivir for treating the novel-coronavirus pneumonia at present and can be applied to development of drugs for treating the novel-coronavirus pneumonia..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 29. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU HONGHAI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-12-29, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN112142810 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011482745 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011482745 | ||
| 003 | DE-627 | ||
| 005 | 20230504090814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210601s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA011482745 | ||
| 035 | |a (EPA)CN112142810 | ||
| 035 | |a (EPA)73894340 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU HONGHAI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nucleotide bisaminophosphate compound, pharmaceutical composition thereof, preparation method for nucleotide bisaminophosphate compound and application of nucleotide bisaminophosphate compound |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-12-29, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 | ||
| 520 | |a The invention belongs to the technical field of medicines and discloses a nucleotide bisaminophosphate compound, a pharmaceutical composition thereof, a preparation method for the nucleotide bisaminophosphate compound and application of the nucleotide bisaminophosphate compound, particularly in treatment on novel-coronavirus pneumonia. Tests prove that the compound disclosed by the invention has the activity of inhibiting replication of 2019-nCoV virus; and meanwhile, the nucleotide bisaminophosphate compound has the advantages of higher in-vitro activity, bigger development coefficient and the like compared with a drug, i.e., Remdesivir for treating the novel-coronavirus pneumonia at present and can be applied to development of drugs for treating the novel-coronavirus pneumonia. | ||
| 650 | 4 | |a C07H: Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids (derivatives of aldonic or saccharic acids c07c, c07d;aldonic acids, saccharic acids c07c0059105000, c07c0059285000;cyanohydrins c07c0255160000;glycals c07d;compounds of unknown constitution c07g;polysaccharides, derivatives thereof c08b;dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification c12n0015000000;sugar industry c13) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/73894340/publication/CN112142810A1?q=CN112142810 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 29 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 29 |c 12 | ||